Kazuki Takasaki

Publication Activity (10 Years)

Years Active: 2017-2022
Publications (10 Years): 6

Top Topics

Venous Thromboembolism

Replacement Therapy

Endometrial Cancer

Top Venues

BMJ case reports

Cancer chemotherapy and pharmacology

Medical oncology (Northwood, London, England)

The journal of obstetrics and gynaecology research

This page only lists publications with an associated author ORCID identifier.

Publications

Kazuki Takasaki, Hirofumi Henmi, Utako Ikeda, Toshiaki Endo, Atsushi Azumaguchi, Kazunori Nagasaka
Intrauterine adhesion after hysteroscopic myomectomy of submucous myomas. The journal of obstetrics and gynaecology research (2022)
Tsubasa Ito, Kazuki Takasaki, Minori Takada, Akira Tomioka
Ischaemic colitis diagnosed by sigmoidoscopy during pregnancy. BMJ case reports 14 (5) (2021)
Kazuki Takasaki, Takazumi Tsunenari, Kazuma Mori, Satsuki Aochi
COVID-19 with essential thrombocythemia treated with apixaban for antithrombotic prophylaxis. BMJ case reports 14 (11) (2021)
Kazuki Takasaki, Morikazu Miyamoto, Masashi Takano, Hiroaki Soyama, Tadashi Aoyama, Hiroko Matuura, Kento Kato, Takahiro Sakamoto, Mika Kuwahara, Hideki Iwahashi, Hiroki Ishibashi, Tomoyuki Yoshikawa, Kenichi Furuya
Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis. Cancer chemotherapy and pharmacology 81 (5) (2018)
Morikazu Miyamoto, Masashi Takano, Mika Kuwahara, Hiroaki Soyama, Kento Kato, Hiroko Matuura, Takahiro Sakamoto, Kazuki Takasaki, Tadashi Aoyama, Tomoyuki Yoshikawa, Kenichi Furuya
Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review. Cancer chemotherapy and pharmacology 81 (1) (2017)
Hiroaki Soyama, Morikazu Miyamoto, Masashi Takano, Tadashi Aoyama, Hiroko Matuura, Takahiro Sakamoto, Kazuki Takasaki, Mika Kuwahara, Kento Kato, Tomoyuki Yoshikawa, Hideki Iwahashi, Hitoshi Tsuda, Kenichi Furuya
Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin. Medical oncology (Northwood, London, England) 34 (12) (2017)